Physician profile
Claire E Ward
NPI 1043531544
$3,229.34
in general payments reported to CMS, 2019-2025
22 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.00 · 2020: $16.10 · 2023: $186 · 2024: $1,328 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142 · Education: $59.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.88 |
| Education | $59.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $730.59 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $648.24 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Novartis Pharmaceuticals Corporation | $254.58 | 2024-2025 | |
| Genentech USA, INC. | $229.00 | 2024-2025 | Xolair |
| Pharming Healthcare, INC. | $195.66 | 2024-2025 | Ruconest, Joenja |
| Amgen INC. | $195.07 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $191.38 | 2024-2025 | Cuvitru, Eohilia, Glassia |
| Csl Behring | $143.23 | 2023-2025 | Hizentra, Andembry, Haegarda |
| Pfizer INC. | $87.58 | 2024-2025 | |
| Genzyme Corporation | $82.78 | 2023-2025 | |
| Blueprint Medicines Corporation | $77.69 | 2024-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $66.72 | 2024-2025 | Dupixent |
| Incyte Corporation | $47.33 | 2025 | Opzelura |
| Ionis Pharmaceuticals, INC. | $45.59 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $44.75 | 2024-2025 | Orladeyo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $42.23 | 2025 | Neffy |
| Grifols USA, LLC | $38.59 | 2025 | Xembify |
| Greer Laboratories, INC. | $35.10 | 2024-2025 | Palforzia, Oralair |
| Cycle Pharmaceuticals INC | $22.52 | 2024 | Sajazir |
| Organon LLC | $22.48 | 2025 | Vtama |
| Lilly USA, LLC | $14.60 | 2025 | Ebglyss |
| Leo Pharma INC. | $13.63 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.